行业组件数据 · 2026

活性药物成分

Active Pharmaceutical Ingredient (API) is the biologically active component in pharmaceutical tablets responsible for therapeutic effects.

技术定义与适配语境
典型 活性药物成分 会按材料、尺寸公差、适配关系和失效风险在 化学制造 中评估。

Active Pharmaceutical Ingredient (API) is the substance in a pharmaceutical drug that produces the intended pharmacological effect. In tablet manufacturing, APIs are combined with excipients through processes like granulation, blending, and compression to form the final dosage form. APIs must meet strict purity, potency, and stability standards as defined by pharmacopeias and regulatory agencies.

组件规格

定义
Active Pharmaceutical Ingredient (API) is the substance in a pharmaceutical drug that produces the intended pharmacological effect. In tablet manufacturing, APIs are combined with excipients through processes like granulation, blending, and compression to form the final dosage form. APIs must meet strict purity, potency, and stability standards as defined by pharmacopeias and regulatory agencies.
工作原理
APIs work through specific biochemical interactions with biological targets (e.g., receptors, enzymes) to produce therapeutic effects. In tablet formulation, APIs are uniformly distributed within excipient matrices to ensure consistent dosage delivery upon ingestion and dissolution.
材料
APIs are typically organic compounds (small molecules) or biologics (proteinspeptides) with defined chemical structures. Common materials include synthetic chemicalsplant extractsor fermentation products. Specifications include chemical purity (>98-99.5%)particle size distribution (10-200 μm)polymorphism controland moisture content (<0.5%).
Purity
≥98.5%
Potency
95-105% of labeled amount
Stability
24-month shelf life under specified conditions
Solubility
Water-soluble or lipid-soluble as required
Bulk Density
0.4-0.8 g/cm³
Particle Size
D90 < 150 μm
标准
ISO 9001ISO 13485ICH Q7USPEPJP

行业分类与别名

活性药物成分 的常用贸易名称、技术标识和检索关键词。

上级产品

该组件会出现在以下整机或工业产品中。

FMEA · 风险与缓解

诱因 → 失效模式 → 工程缓解

Inadequate purification during synthesis->High impurity levels exceeding specifications->Implement multi-step purification processes and in-process controls
Improper storage conditions->API degradation reducing potency->Maintain controlled temperature and humidity storage with monitoring
Particle size variation->Inconsistent tablet content uniformity->Implement milling and sieving controls with regular particle size analysis

工业生态与工程逻辑

0
Contamination with impurities
1
Polymorphism changes affecting bioavailability
2
Degradation during storage
3
Cross-contamination in manufacturing
4
Regulatory non-compliance

合规与检测

tolerance
±5% for assay, ±0.1% for related substances, ±10% for particle size distribution
test method
HPLC for purity, USP dissolution testing, Karl Fischer for moisture, laser diffraction for particle size, microbial enumeration per USP <61>

制造该组件的工厂

来自 CNFX 组件能力表的相关制造商资料。

制造商列表用于前期研究和供应商能力理解,不代表认证、排名或交易担保。

采购评估维度

不是客户评论,也不是实时热度。以下维度用于前期 RFQ 准备和供应商评估。

技术文档
4/5
制造能力
4/5
可检验性
5/5
供应商透明度
3/5

这些分值是采购评估维度示例,不代表真实客户评分、具体国家买家反馈或实时询盘。

相关组件

常见问题

What is the difference between API and finished dosage form?

API is the pure drug substance that provides therapeutic effect, while finished dosage form (like tablets) contains API combined with excipients for administration.

How are APIs tested for quality?

APIs undergo rigorous testing including identity, assay, impurity profiling, residual solvents, microbial limits, and physical characterization per pharmacopeial standards.

What are common sources of APIs?

APIs are sourced from chemical synthesis, fermentation, extraction from natural sources, or recombinant DNA technology for biologics.

我可以直接联系工厂吗?

CNFX 是开放目录,不是交易平台或采购代理。工厂资料和表单用于帮助你准备直接沟通。

CNFX Industrial Component Index · 化学制造

数据基础

CNFX 制造商资料、技术分类、公开产品信息和持续合理性检查。

初步技术归类
本页用于结构化准备研究、RFQ 和供应商评估,不替代买方自己的供应商资质审查、标准核验和技术批准。

请求制造能力信息: 活性药物成分

说明目标数量、应用场景、交期和关键技术要求,用于准备 RFQ 或供应商评估。

谢谢,信息已发送。
谢谢,信息已收到。

需要制造 活性药物成分?

对比具备该组件加工或装配能力的制造商资料。

创建制造商档案 联系我们
上一个组件
活性药物成分
下一个组件
流变改性剂
URN:CNFX:ME:UNIT:ACTIVE_PHARMACEUTICAL_INGREDIENT_API_